1. Home
  2. VTMX vs EWTX Comparison

VTMX vs EWTX Comparison

Compare VTMX & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)

VTMX

Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)

HOLD

Current Price

$31.31

Market Cap

2.4B

Sector

N/A

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$27.39

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTMX
EWTX
Founded
1998
2017
Country
Mexico
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.5B
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
VTMX
EWTX
Price
$31.31
$27.39
Analyst Decision
Hold
Buy
Analyst Count
3
8
Target Price
$30.50
$34.13
AVG Volume (30 Days)
55.7K
1.7M
Earning Date
10-23-2025
11-06-2025
Dividend Yield
2.16%
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
$271,805,969.00
N/A
Revenue This Year
$13.43
N/A
Revenue Next Year
$9.87
N/A
P/E Ratio
$44.70
N/A
Revenue Growth
11.74
N/A
52 Week Low
$21.30
$10.60
52 Week High
$32.21
$30.48

Technical Indicators

Market Signals
Indicator
VTMX
EWTX
Relative Strength Index (RSI) 56.70 62.58
Support Level $30.21 $19.76
Resistance Level $31.39 $25.56
Average True Range (ATR) 0.77 2.18
MACD -0.05 -0.08
Stochastic Oscillator 55.88 99.87

Price Performance

Historical Comparison
VTMX
EWTX

About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)

Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: